Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03773302
Title Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors QED Therapeutics, Inc.
Indications

cholangiocarcinoma

Therapies

Cisplatin + Gemcitabine

Infigratinib

Age Groups: adult | senior
Covered Countries USA | CAN

Additional content available in CKB BOOST